NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

HeartSciences Inc. (HSCS) Stock Analysis

HeartSciences Inc. (HSCS) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

HSCS

$3.56

+$0.43 (+13.74%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HSCS with… →

HSCS Key Statistics

As of Oct 21, 2026
Trading
Open
$3.20
Previous Close
$3.13
Day's Range
3.20–3.68
52-Week Range
1.63–5.25
Volume
235.99K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.78
Valuation
Market Cap
$17.24M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3,815.96
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.21
Financials (FY)
Revenue (FY)
$4.32K−0.71%
Net Income (FY)
−$9.14M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.84M
1-Year Return
+5.33%
Dividend and dates
Avg Volume
159.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HSCS closed at $3.56, +5.33% over 1 year.

HeartSciences Inc. (HSCS) has a market capitalization of $17.24M.

In fiscal 2025, HSCS reported revenue of $4.32K.

HSCS Stock Return by Calendar Year

HeartSciences Inc. (HSCS) return since Jun 2022: what $10,000 became

1 year
$10,000 $10,533
+5.33%
3 years
$10,000 $920
−90.80%
Since Jun 2022
$10,000 $147
−98.53%

If you had invested $10,000 in HeartSciences Inc. (HSCS) at the close on June 16, 2022, the earliest close on record here, it would have been worth $147 at the close on October 21, 2026: −98.53% in total, −62.11% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+15.21%
2025−19.11%
2024−77.66%
2023−79.64%
2022 (partial year)−65.29%

As of October 21, 2026.

HSCS Revenue and Earnings by Fiscal Year

FY ends April
Fiscal yearRevenueNet incomeNet margin
2025$4.32K−$9.14M−211,666.5%
2024$4.35K−$8.77M−201,499.5%
2023$18.60K−$6.61M−35,511.9%
2022$5.15K−$6.35M−123,384.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.32K$2.55K−$8.41M−$9.14M−211,666.5%
2024$4.35K$2.47K−$8.35M−$8.77M−201,499.5%
2023$18.60K$12.52K−$6.31M−$6.61M−35,511.9%
2022$5.15K$2.35K−$6.11M−$6.35M−123,384.3%

Annual figures as reported, in the company's reporting currency. As of April 30, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

HeartSciences Inc. (HSCS) carries a market capitalisation of $17.24M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 14.

The 52-week range on file runs from $1.63 to $5.25. HSCS last closed at $3.56 on October 21, 2026. That is +$0.43 (+13.74%) against the previous close. The latest close sits 118.4% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.32K. Against the prior fiscal year total of $4.35K, that is a change of −0.71%. The same year closed with a net loss of $9.14M. Earnings per share on a trailing basis come to −3.21.

Across the 4 fiscal years on file, revenue moves from $5.15K in 2022 to $4.32K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3,815.96 times revenue. On price-to-sales that is 1,508.5 times the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.78. Annualized volatility over the trailing 4 years is 160.57%. Over the trailing twelve months the total return is +5.33%. Measured over 3 years, that is −54.86% a year compounded.

Growth & Income

The record shows no dividend for HSCS.

So far in 2026 the total return is +15.21%. Across the complete calendar years on file, 2025 returned −19.11% and 2023 returned −79.64%. Of the 3 complete calendar years on file, 0 finished higher.

Peer Comparison

HeartSciences Inc. (HSCS) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
HeartSciences Inc. HSCS $17.24M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. HeartSciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About HeartSciences Inc.

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

Visit website →